Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Lurasidone in Healthy Chinese Subjects
NCT02174523Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Apr 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma. Primary endpoints: Lurasidone Maximum Plasma Concentration at Day 8, Lurasidone Area Under the Curve 0-24h at Day 8 and 8 more. Started Apr 2014; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02174523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174523.